Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Basilea Pharmaceutica Ltd.

www.basileapharma.com

Latest From Basilea Pharmaceutica Ltd.

Basilea's Ceftobiprole On TARGET, Needs Positive Second Study For US

The first pivotal Phase III study required for US approval of Basilea’s ceftobiprole has reported positive topline results; a second study is expected to read out in 2021.

 

Clinical Trials Infectious Diseases

Basilea-Pfizer’s Cresemba Heads For Indian Debut

Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its existing portfolio in the segment. Pricing of the product will be keenly watched.

Policy & Regulation India

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Deals Business Strategies

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Basilea Pharmaceutica AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Basilea Pharmaceutica Ltd.
  • Senior Management
  • Ronald Scott, MD, CEO
    Donato Spota, CFO
    Laurenz Kellenberger, PhD, CSO
    David Veitch, Chief Commercial Officer
    Marc Engelhardt, MD, PhD, CMO
    Gerrit Hauck, PhD, CTO
  • Contact Info
  • Basilea Pharmaceutica Ltd.
    Phone: (41) 61 606 11 11
    Grenzacherstrasse 487
    Basel, 4005
    Switzerland
UsernamePublicRestriction

Register